Yiyao \China

Step 2 (Validation): Sign outcome-based pilot with one mid-size insurer (5,000 covered diabetics). Charge $15/patient/month with 50% bonus if cohort achieves >0.7% average HbA1c reduction. Expand AI capabilities: add exercise coaching, mental health check-ins (diabetes + depression comorbidity), and family caregiver portal. Integrate with China's national health insurance system for claims data. Target 80% patient retention at 6 months. Cost: $300K (6 months, scale to 8-person team).

Step 3 (Growth): Launch employer wellness channel targeting China's 200M+ white-collar workers (high diabetes prevalence, strong employer health benefits). Offer $200/employee/year for comprehensive diabetes prevention + management. Build viral loop: patients who hit HbA1c goals get $50 credit toward CGM supplies, incentivizing adherence. Expand to 50,000 active patients across 3 provinces. Add AI-powered complication prediction (retinopathy, neuropathy risk scoring) to increase clinical value. Cost: $800K (12 months, 20-person team).

Step 4 (Moat): Develop proprietary clinical dataset of 100K+ Chinese diabetic patients with longitudinal CGM + outcomes data—the largest in China. Use this to train specialized medical AI models that outperform generic LLMs on diabetes management. License these models to hospitals and other digital health platforms (B2B revenue stream). Expand to hypertension and cardiovascular disease using same AI infrastructure. Negotiate exclusive partnerships with top-3 CGM manufacturers for China distribution. Build regulatory moat by working with NMPA (China's FDA) to get ChronicCare classified as Class II medical device software, creating 18-24 month barrier to entry for competitors.